Medeon Biodesign Valuation
| 6499 Stock | TWD 40.00 0.40 1.01% |
At this time, the firm appears to be fairly valued. Medeon Biodesign secures a last-minute Real Value of NT$38.8 per share. The latest price of the firm is NT$40.0. Our model forecasts the value of Medeon Biodesign from analyzing the firm fundamentals such as Current Valuation of 3.37 B, return on equity of -0.1, and Profit Margin of (1.31) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Medeon Biodesign's price fluctuation is very steady at this time. Calculation of the real value of Medeon Biodesign is based on 3 months time horizon. Increasing Medeon Biodesign's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medeon stock is determined by what a typical buyer is willing to pay for full or partial control of Medeon Biodesign. Since Medeon Biodesign is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medeon Stock. However, Medeon Biodesign's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 40.0 | Real 38.8 | Hype 40.0 |
The intrinsic value of Medeon Biodesign's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medeon Biodesign's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medeon Biodesign helps investors to forecast how Medeon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medeon Biodesign more accurately as focusing exclusively on Medeon Biodesign's fundamentals will not take into account other important factors: Medeon Biodesign Total Value Analysis
Medeon Biodesign is presently anticipated to have takeover price of 3.37 B with market capitalization of 5 B, debt of 0, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medeon Biodesign fundamentals before making investing decisions based on enterprise value of the companyMedeon Biodesign Investor Information
About 50.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.29. In the past many companies with similar price-to-book ratios have beat the market. Medeon Biodesign recorded earning per share (EPS) of 30.41. The entity last dividend was issued on the 22nd of August 2022. The firm had 1000:1049 split on the 22nd of August 2023. Based on the analysis of Medeon Biodesign's profitability, liquidity, and operating efficiency, Medeon Biodesign is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Medeon Biodesign Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medeon Biodesign has an asset utilization ratio of 1.58 percent. This indicates that the Company is making NT$0.0158 for each dollar of assets. An increasing asset utilization means that Medeon Biodesign is more efficient with each dollar of assets it utilizes for everyday operations.Medeon Biodesign Ownership Allocation
Medeon Biodesign maintains a total of 87.64 Million outstanding shares. Medeon Biodesign holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medeon Biodesign Profitability Analysis
The company reported the revenue of 68.96 M. Net Income was 2.08 B with profit before overhead, payroll, taxes, and interest of 28.63 M.About Medeon Biodesign Valuation
Our relative valuation model uses a comparative analysis of Medeon Biodesign. We calculate exposure to Medeon Biodesign's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medeon Biodesign's related companies.8 Steps to conduct Medeon Biodesign's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Medeon Biodesign's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medeon Biodesign's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medeon Biodesign's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medeon Biodesign's revenue streams: Identify Medeon Biodesign's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medeon Biodesign's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medeon Biodesign's growth potential: Evaluate Medeon Biodesign's management, business model, and growth potential.
- Determine Medeon Biodesign's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medeon Biodesign's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Medeon Stock Analysis
When running Medeon Biodesign's price analysis, check to measure Medeon Biodesign's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medeon Biodesign is operating at the current time. Most of Medeon Biodesign's value examination focuses on studying past and present price action to predict the probability of Medeon Biodesign's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medeon Biodesign's price. Additionally, you may evaluate how the addition of Medeon Biodesign to your portfolios can decrease your overall portfolio volatility.